for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Udg Healthcare PLC

UDG.L

Latest Trade

1,079.00GBp

Change

4.00(+0.37%)

Volume

358,278

Today's Range

1,075.00

 - 

1,079.00

52 Week Range

688.50

 - 

1,099.00

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
1,075.00
Open
1,075.00
Volume
358,278
3M AVG Volume
48.50
Today's High
1,079.00
Today's Low
1,075.00
52 Week High
1,099.00
52 Week Low
688.50
Shares Out (MIL)
251.98
Market Cap (MIL)
2,708.72
Forward P/E
27.62
Dividend (Yield %)
0.82

Next Event

Q3 2021 UDG Healthcare plc Trading Statement Release

Latest Developments

More

UDG Healthcare Says Re-Convened Scheme Meeting On Nenelite Offer To Be Held On July 22

UDG Healthcare Gets Cash Offer From Affiliate Of Clayton, Dubilier & Rice LLC

Udg Healthcare Sees FY21 Constant Currency Adj Operating Profit Growth Of 12%-14%

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Udg Healthcare PLC

UDG Healthcare PLC is an Ireland-based company that provides healthcare advisory, communications, commercial, clinical and packaging services. The Company operates across two divisions: Ashfield and Sharp. Ashfield provides advisory, communication, commercial and clinical services for the pharmaceutical and healthcare industries and provides field and contact center sales teams, healthcare communications, patient support, audit, advisory, medical information and event management services to healthcare companies. Sharp provides contract commercial packaging and clinical trial packaging services for the pharmaceutical and healthcare industries. Sharp operates facilities in the United States and Europe.

Industry

Biotechnology & Drugs

Contact Info

River Walk 20

Ireland

+353.1.4689000

http://www.udghealthcare.com

Executive Leadership

Shane M. Cooke

Non-Executive Chairman of the Board

Brendan McAtamney

Chief Executive Officer, Executive Director

Nigel Clerkin

Chief Financial Officer, Executive Director

Greg Flynn

President of Ashfield Clinical and Commercial

Kevin Orfan

President, Sharp Corporation

Key Stats

2.63 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

1.3K

2019

1.3K

2020

1.3K

2021(E)

1.3K
EPS (USD)

2018

0.460

2019

0.470

2020

0.480

2021(E)

0.533
Price To Earnings (TTM)
44.20
Price To Sales (TTM)
2.99
Price To Book (MRQ)
3.60
Price To Cash Flow (TTM)
22.31
Total Debt To Equity (MRQ)
36.64
LT Debt To Equity (MRQ)
34.92
Return on Investment (TTM)
5.92
Return on Equity (TTM)
4.79

Latest News

Latest News

CD&R confirms sweetened bid to take UDG Healthcare private at $3.83 billion

UDG Healthcare said on Tuesday private equity firm Clayton, Dubilier & Rice (CD&R) has raised its offer to buy the London-listed firm to 2.76 billion pounds ($3.83 billion).

CD&R confirms sweetened bid to take UDG Healthcare private at $3.83 bln

UDG Healthcare said on Tuesday private equity firm Clayton, Dubilier & Rice (CD&R) has raised its offer to buy the London-listed firm to 2.76 billion pounds ($3.83 billion).

Top UDG shareholder plans to back CD&R deal in case of higher offer

UDG Healthcare's largest shareholder said on Monday it plans to back CD&R's offer for the British company if the private equity firm raised its bid to 2.72 billion pounds.

CD&R poised to sweeten UDG take-private bid after investor opposition

Private equity firm Clayton, Dubilier & Rice (CD&R) could increase its offer for UDG Healthcare to 2.72 billion pounds ($3.79 billion), the London-listed group said on Friday, following shareholder opposition to a previously agreed bid.

Private equity group CD&R plans to raise offer for UDG Healthcare

UDG Healthcare said on Friday private equity firm Clayton, Dubilier & Rice (CD&R) was considering raising its offer to buy the healthcare company to 1,080 pence per share.

Activist fund Elliott picks up stake in takeover target UDG Healthcare

Activist investor Elliott Investment Management disclosed a stake of about 3.1% in UDG Healthcare, weeks after the pharmaceutical services company agreed to be taken over for 2.6 billion pounds ($3.69 billion).

Top UDG shareholder says private equity bid undervalues company

The largest shareholder in London-listed UDG Healthcare [UDG.L] said a $3.7 billion offer for the company from private equity firm Clayton, Dubilier & Rice was "opportunistic and significantly undervalues UDG and its prospects".

UPDATE 2-Private equity firm to buy UDG Healthcare in $3.7 bln deal

Private equity firm Clayton, Dubilier & Rice (CD&R) has agreed to buy London-listed UDG Healthcare for 2.6 billion pounds ($3.7 billion), the pharmaceuticals services company said on Wednesday.

BRIEF-UDG Healthcare Sees Lower Activity Levels Than Previously Anticipated During H2 Of FY20

* SAYS H2 FY20 PERFORMANCE EXPECTED TO BE IMPACTED BY COVID-19

BRIEF-UDG Healthcare Says COVID-19 Expected To Impact H2 FY20 Performance

* UDG HEALTHCARE PLC SAYS STRONG H1 FY20, WELL AHEAD OF PRIOR YEAR

BUZZ-UDG Healthcare: Dual acquisitions boosts FY outlook

** Shares of international healthcare services provider UDG Healthcare Plc up 1.6% at 663 pence

CORRECTED-Ireland's UDG Healthcare expects rise in FY profit after Q1 growth

Ireland-based UDG Healthcare Plc said on Tuesday its first-quarter pretax profit was higher than a year earlier, boosted by gains from its recent acquisitions and growth across its businesses.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up